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Abstract
Background: Core decompression is a common surgical technique to treat osteonecrosis of the femoral head. The
aim of this study is to evaluate the effect of the parameters “age” and “sex” on the outcome of this type of treatment.
Methods: A prospective cohort study was performed. Eighty-six osteonecrotic hips with a mean follow-up of 32.5months
(± 24.8) after advanced core decompression were analysed regarding age- and sex-dependent treatment failure.
Additionally, the modified Harris Hip Score and Numeric Rating Scale were compared regarding the parameters age and sex.
Results: The mean hip survival of the male participants was 51.3months (39.4% treatment failure), whereas females
presented a longer, thus not significant, mean survival of 61.4months (30% therapy failure; p = 0.48). The further evaluation
revealed significantly better survival in the patients aged < 40 years (mean survival 66.09months, 16% treatment failure) in
comparison to those aged ≥ 40 years (mean survival 50.14months, 46% therapy failure; p = 0.03). The modified Harris Hip
Score and Numeric Rating Scale results of patients whose treatment did not fail during the study period were similar,
irrespective of the patient’s sex or age.
Conclusions: The study shows that the number of therapy failures is significantly higher in older patients, with 40 years of
age marking the borderline. Patients’ sex does not seem to affect the outcome of treatment, and postoperative clinical
scores appear to be identical with individuals not affected by therapy failure. Since age and sex are unalterable parameters,
the study helps to provide valuable predictions regarding the chances of long-term hip survival after treatment of
osteonecrosis.
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Background
Osteonecrosis of the femoral head (ONFH) is a patho-
logical condition of the hip joint characterized by impaired
blood supply which induces progressing structural instabil-
ity. Missed or delayed treatment regularly results in collapse
of the femoral head with arthroplasty being the only
remaining treatment option [1, 2]. It is supposed that
ONFH is based on a multifactorial genesis of which several
risk factors such as corticosteroid treatment, coagulopathies
and heavy alcohol and nicotine consumption have been
identified [3, 4]. The average prevalence is estimated to be
29 out of 100,000 each year with a peak in age distribution
between 30 and 50 years. A further typical finding is the
predominant occurrence of ONFH in the male sex [5, 6].
As ONFH harbours the severe risk of irreversible dam-
age to the affected hip, it is essential that treatment should
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be commenced as soon as possible. Non-surgical options
have been described for treatment of early-stage ONFH
that is often characterized by diffuse bone marrow oedema
[7–9]. In that context iloprost, enoxaparin and bisphos-
phonate treatment have been reported [10–12]. Moreover,
recent studies showed extracorporeal shock wave therapy
to be a further promising approach in the management of
early-stage ONFH [13–15].
However, to the present day, surgical procedures still
are the therapy of choice in most cases, especially when
necrotic zones have begun to demarcate [3, 16]. Several
techniques have been published with core decompres-
sion and its variations being one of the most frequently
performed procedures. All types of core decompression
aim at pain reduction and long-term preservation of the
femoral head provided that it has not yet collapsed [3,
17]. Although differences in the rate of hip survival have
been reported depending on the type of procedure per-
formed, there are further factors that distinctly limit
therapy success. Treatment of advanced ONFH stages as
described in the ARCO and Steinberg classifications is
more likely to fail than treatment of early ones [3, 18–
20]. Lesion size also seems to have a significant effect on
outcome, with larger lesions often resulting in joint-line
collapse despite surgery [21]. Concomitant pathologies
of the hip joint such as the femoroacetabular impinge-
ment syndrome seem to reduce the rate of therapy suc-
cess in ONFH even further [22]. Furthermore, therapy is
also more likely to be jeopardised if known risk factors
such as ongoing corticosteroid treatment or addictive al-
cohol consumption cannot be eliminated.
As for the parameters “age” and “sex”, their influence
on ONFH therapy outcome has so far not been suffi-
ciently evaluated. Shimizu et al. were able to show that
alcohol-induced ONFH was more often triggered in
male rats than in females and thereby supposed the
presence of unknown sex-based factors for its predomin-
ant occurrence in men [23]. However, they did not pro-
vide a prognosis concerning therapy outcome depending
on sex. The same applies for the parameter “age”. We
know the age distribution for the occurrence of ONFH
but nothing about its influence on therapy success. This
study therefore aims to present the age- and sex-
dependent outcome of ONFH therapy through advanced
core decompression.
Methods
A prospective, non-randomized design was chosen (level
II-prospective cohort study). The study was approved by
the institutional review board of the University of
Duisburg-Essen, and informed consent was obtained
from all participants. Conventional x-ray and magnetic
resonance imaging were used to diagnose ONFH. In
order to avoid a stage-dependent outcome bias, only
patients with ARCO and Steinberg stage 2 lesions were
included [20, 24]. All patients underwent detailed pre-
operative physical examination and were followed up
regularly at the Department of Orthopaedics and
Traumatology of the University Hospital Essen. The re-
corded parameters included the modified Harris Hip
Score (mHHS) for evaluation of hip function and the
numeric rating scale (NRS) for pain quantification [25,
26]. ONFH was treated solely by advanced core decom-
pression (ACD) and its modified version (mACD) be-
tween the years 2011 and 2016 as described by
Landgraeber et al. [17, 27]. Both methods are character-
ized by fluoroscopic-guided drilling into the defect zone
and removal of the necrotic tissue using an expandable
reamer. Whereas intraosseous defects were filled solely
with synthetic bone substitute composed of calcium sul-
fate (CaSO4)/calcium phosphate (CaPO4) in conven-
tional ACD, a mixture of autologous cancellous bone
from the femoral neck and the same synthetic bone sub-
stitute was used in cases of mACD.
The study collective included 71 patients with ONFH
resulting in a total number of 86 affected hips due to 15
cases of bilateral occurrence. The follow-up period was
termed for 2 years with postoperative assessment points
set at 6 weeks, 6 months, 12 months and 24months. As
numerous patients continued to regularly present them-
selves, a longer overall follow-up period of 32.5 months
was calculated. The primary objective of the study was
to evaluate the long-term results of ONFH treatment by
ACD considering the parameters “age” and “sex” in par-
ticular. In order to assess the treatment outcome, sub-
groups on the basis of these two specific parameters
were formed. Detailed baseline characteristics of the en-
tire study collective as well as the created subgroups are
presented in Table 1 and Table 2.
We proposed the hypothesis that the higher a patient’s
age, the lower the chances of therapy success, whereas
the patient’s sex does not affect therapy results. The pri-
mary study endpoint was defined as the need for arthro-
plasty due to radiological evidence of collapse of the
femoral head. The secondary endpoint was set as the
evidence of age- or sex-dependent differences in joint
Table 1 Study collective’s baseline characteristics relating to the
total number of hips affected by ONFH
Study collective—ONFH-hips total N = 86
ONFH-occurrence (count), monolateral/bilateral 56/15
Sex (count), male/female 66/20
Age (years), mean ± SD/min./max. 46.8 ± 12.2/21.8/69.7
Treatment type (count), ACD/mACD 46/40
Follow-up (months), mean ± SD 32.5 ± 24.8
SD standard deviation
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function or pain level by analysing the postoperative
mHHS and NRS scores.
As it is known that the treatment outcome of ONFH
depends on several co-factors, the subgroups were fur-
ther analysed regarding the presence and distribution of
possible confounders. The parameters recorded in this
context include the size of the necrotic lesion (A–C ac-
cording the ARCO and Steinberg classifications), the
presence of risk factors (immunosuppressive therapy,
high-dose corticosteroid treatment, abuse of alcohol and
nicotine and coagulation disorders) and radiological evi-
dence of cam-type deformity of the affected hip using
the alpha angle according to Nötzli [21, 22, 28, 29].
Statistical analysis was performed using SPSS® Statis-
tics (Version 21.0, IBM®). Concerning the primary study
endpoint, a Kaplan-Meier survival analysis was per-
formed separately for the parameters “age” and “sex”.
The log-rank test was used to examine significant statis-
tical differences. Significance level was set at p < 0.05
(significant). For comparison of pre- and postoperative
mHHS and NRS (secondary study endpoint) sample dis-
tribution was tested using the Kolmogorov-Smirnov test.
In case of normal distribution, the t test for independent
and dependent parametric samples was used; otherwise,
the Wilcoxon rank-sum test was utilized. Patients with
treatment failure in the postoperative course were not
considered. Regarding the influence of possible con-
founders, cross tables combined with the chi-square test
were used to describe their distribution in the subgroups
and thereby check for relevant differences.
Results
Primary study endpoint—treatment failure
In the study collective as a whole, collapse of the femoral
head and thereby failure of treatment was identified in
32 hips (37.2%) during the follow-up period. As regards
the patients’ sex, treatment failed in 26 out of 66 male
hips (39.4%) after an average of 11.15 (± 8.87) months.
For the female participants, treatment failure was regis-
tered in 6 out of 20 hips (30%) after an average 6.33 (±
3.68) months (Table 3). Using the Kaplan-Meier survival
estimator, a mean survival time of 51.3 months was cal-
culated for the male hips, while the mean survival of the
female hips was 61.4 months. However, despite the bet-
ter survival of the female hips, the differences were not
statistically significant in the log-rank test (p = 0.48)
(Fig. 1).
Regarding the parameter “age”, therapy failure was
documented in 2 cases (22.22%) in subgroup 1 (< 30
years) after an average of 4.00 (± 4.24) months. Sub-
group 2 (≥ 30/< 40 years) also had 2 cases (12.50%, 5.50
months ± 0.71) of treatment failure, whereas subgroups
Table 2 Baseline characteristics of the formed age- and sex-dependent ONFH-subgroups
Subgroup “Age” ONFH, mono-/bilateral
(count)
Sex, male/female
(count)
Age, years (mean ±
SD)
Treatment, ACD/mACD
(count)
Follow-up, months (mean
± SD)
< 30 years (N = 9) 8/1 6/3 n.a. 5/4 33.41 ± 24.61
≥ 30/< 40 years (N
= 16)
11/5 10/6 n.a. 7/9 39.18 ± 26.26
≥ 40/< 50 years (N
= 27)
23/4 25/2 n.a. 15/12 34.49 ± 24.11
≥ 50 years (N = 34) 29/5 25/9 n.a. 19/15 27.44 ± 24.90
Subgroup “Sex”
Male (N = 66) 52/14 n.a. 47.34 ± 11.74 33/33 29.67 ± 23.15
Female (N = 20) 19/1 n.a. 45.16 ± 13.65 13/7 41.68 ± 28.49
SD standard deviation
Table 3 Age- and sex-dependent therapy outcome in total numbers and rounded percentages
Study collective Therapy failure (count and percentage)
No Yes Subgroup total
Subgroup 1 (< 30 years) Total male/female 7 (77.78%)
5/2 (55.56%/22.22%)
2 (22.22%)
1/1 (11.11%/11.11%)
9 (100%)
6/3 (66.67%/33.33%)
Subgroup 2 (≥ 30/< 40 years) Total male/female 14 (87.50%)
9/5 (56.25%/31.25%)
2 (12.50%)
1/1 (6.25%/6.25%)
16 (100%)
10/6 (62.50%/37.50%)
Subgroup 3 (≥ 40/< 50 years) Total male/female 16 (59.26%)
14/2 (51.85%/7.41%)
11 (40.74%)
11/0 (40.75%/0%)
27 (100%)
25/2 (92.59%/7.41%)
Subgroup 4 (≥ 50 years) Total male/female 17 (50.00%)
12/5 (35.29%/14.71%)
17 (50.00%)
13/4 (38.24%/11.76%)
34 (100%)
25/9 (73.53%/26.47%)
Total 54 (62.79%) 32 (37.21%) 86 (100%)
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3 (≥ 40/< 50 years) and 4 (≥ 50 years) presented with 11
(40.47%, 14.91 months ± 11.47) and 17 (50%, 8.53
months ±5.00) unsatisfactory therapy results respectively
(Table 3). As the differences in hip survival between sub-
groups 1 and 2, as well as between subgroups 3 and 4
were not significant during the observation period; a
cut-off was made at the age of 40. By means of Kaplan-
Meier survival analysis, a mean hip survival of 66.09
months was calculated for study participants younger
than 40 years of age. Study subjects older than 40
showed a calculated mean survival of 50.14 months. The
log-rank test showed these differences to be significant
with p = 0.03 (Fig. 2).
Secondary study endpoint—clinical outcome
Evaluation of the preoperative mHHS and NRS data re-
vealed an overall preoperative mean mHHS of 69.93 (±
13.81) and a mean NRS of 3.79 (± 2.14). Overall
postoperative results showed a significant improvement
with the mean final mHHS at 86.13 (± 7.99) and mean
final NRS at 0.96 (± 1.52) at the final postoperative as-
sessment (p < 0.001 each).
Concerning the sex-based subgroups, the mHHS of
the male participants improved from 71.39 (± 13.92) to
86.70 (± 7.82) and the NRS from 3.59 (± 2.22) to 0.75 (±
1.13) over the study period. For the female study pa-
tients, an improvement in the mHHS from 65.10 (±
12.60) to 84.50 (± 8.55), and in the NRS from 4.45 (±
1.73) to 1.57 (± 2.24) was seen. Both subgroups showed
a similar increase in the mean mHHS (15.31 vs. 19.40)
and a similar decrease in the mean NRS (2.84 vs. 2.88)
during follow-up with inter-subgroup differences not be-
ing significant (p > 0.05). Similar changes were also to
be seen at the corresponding follow-up times (Table 4).
It must be mentioned that despite a similar overall im-
provement, the female participants had a distinctly
higher pre- and postoperative NRS score in comparison
to their male counterparts.
As for the parameter “sex”, the alterations in mHHS and
NRS were analogical in the determined age-dependent
subgroups. All subgroups (1 (<30 years), 2 (≥30/<40 years),
3 (≥40/<50 years) and 4 (≥50 years)) showed a similar in-
crease in mHHS, accompanied by a corresponding de-
crease in NRS postoperatively. These changes proved to
be consistent in all subgroups during the whole follow-up
period. Statistical differences appeared to be minimal and
not significant (Table 4, Fig. 3). Patients with therapy fail-
ure during the follow-up period were excluded from the
calculations.
Possible confounders
As the results concerning the primary endpoint indicated
an age-related hip survival after treatment by means of
core decompression, the distribution of possible con-
founders is provided for all age-dependent subgroups. The
recorded parameters “lesion size”, “cam-type deformity”
(on the basis of the alpha angle), “risk factors” and “treat-
ment method” showed a homogenous distribution among
the subgroups. This was confirmed in the corresponding
statistical evaluation using the chi-square test with each p
being far from significance (Table 5).
Discussion
Previous studies have shown the effect of certain param-
eters on the long-term outcome of ONFH therapy.
These known parameters include lesion stage and lesion
size as well as the presence of risk factors and concomi-
tant hip pathologies [3, 21, 22].
As regards the parameter “age”, results show distinct
differences for postoperative hip survival. Whereas the
age-based subgroups “< 30 years” and “≥30 years/<40
years” presented a combined overall hip survival of 84%,
Fig. 1 Kaplan-Meier curve showing sex-dependent hip survival
Fig. 2 Kaplan-Meier curve showing age-dependent hip survival
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older patients aged “≥40 years/<50 years” and “>50 years”
had a significantly lower rate of only 54% of the com-
bined hip survival over the study period. There is there-
fore a strong indication that at around the age of forty,
there is a turning point in the long-term results of
ONFH therapy.
It is known that bone healing in general and regener-
ation after ONFH strongly depends on the capacity of
the individual’s body to repair and remodel the affected
bone [30]. Although the underlying biochemical pro-
cesses are not yet fully understood, a two-phase model
consisting of a disintegrating osteoclast-driven phase
and a bone-rebuilding osteoblast-driven phase is as-
sumed [31]. Both phases are controlled by numerous
growth and signal factors which balance the course of
bone resorption and bone formation (e.g., bone morpho-
genetic proteins (BMP), tumour necrosis factor (TNF)
and osteoprotegerin (OPG)) [32–34]. Basically, these
reparative mechanisms are intended to work throughout
life. Nevertheless, with increasing age, the human organ-
ism’s ability to make sufficient use of them seems to
Table 4 Pre- and (final) postoperative age- and sex-dependent changes in mHHS and NRS
Subgroup “Age” mHHS (mean ± SD) NRS (mean ± SD)
preoperative postoperative preoperative postoperative
Subgroup 1
(< 30 years)
69.67 ± 13.39 84.86 ± 8.01
FU1 88.25 ± 1.89
FU2 89.25 ± 1.26
FU3 87.40 ± 1.67
FU4 83.50 ± 8.57
3.56 ± 2.13 1.00 ± 1.16
FU1 0.75 ± 0.96
FU2 0.50 ± 0.58
FU3 0.80 ± 0.84
FU4 1.00 ± 1.10
Subgroup 2
(≥30/<40 years)
72.31 ± 12.65 87.07 ± 5.21
FU1 83.92 ± 8.14
FU2 87.67 ± 3.72
FU3 86.50 ± 1.00
FU4 86.00 ± 5.07
3.75 ± 2.30 0.93 ± 1.33
FU1 1.00 ± 1.16
FU2 0.83 ± 0.98
FU3 0.75 ± 0.96
FU4 0.86 ± 1.22
Subgroup 3
(≥ 40/< 50 years)
72.19 ± 14.61 86.76 ± 8.93
FU1 85.36 ± 8.13
FU2 88.14 ± 4.45
FU3 89.00 ± 4.87
FU4 87.08 ± 8.14
3.37 ± 2.36 1.12 ± 2.12
FU1 0.91 ± 1.14
FU2 0.43 ± 0.54
FU3 0.50 ± 0.76
FU4 1.57 ± 2.24
Subgroup 4 (≥ 50 years) 67.09 ± 13.84 85.19 ± 9.40
FU1 88.00 ± 4.99
FU2 84.00 ± 8.76
FU3 87.56 ± 4.50
FU4 87.10 ± 5.13
4.21 ± 1.89 0.81 ± 1.11
FU1 0.43 ± 0.65
FU2 0.90 ± 0.99
FU3 0.56 ± 0.73
FU4 0.70 ± 1.06
Subgroup “Sex”
Male 71.39 ± 13.92 86.70 ± 7.82
FU1 86.45 ± 6.39
FU2 86.37 ± 6.74
FU3 87.71 ± 4.08
FU4 86.22 ± 6.35
3.59 ± 2.22 0.75 ± 1.13
FU1 0.83 ± 1.10
FU2 0.74 ± 0.81
FU3 0.57 ± 0.75
FU4 1.07 ± 1.51
Female 65.10 ± 12.60 84.50 ± 8.55
FU1 85.23 ± 8.01
FU2 87.38 ± 5.07
FU3 88.20 ± 2.68
FU4 86.38 ± 8.47
4.45 ± 1.73 1.57 ± 2.24
FU1 0.62 ± 0.65
FU2 0.63 ± 0.92
FU3 0.80 ± 0.84
FU4 1.11 ± 1.63
Total 69.93 ± 13.81 86.13 ± 7.99 3.79 ± 2.14 0.96 ± 1.52
SD standard deviation, FU1 follow-up 6 weeks, FU2 follow-up 6 months, FU3 follow-up 12 months, FU4 follow-up 24 months
Fig. 3 Bar graph illustrating similar age-dependent changes in pre-
and postoperative mHHS and NRS for non-collapsed hips (error bar
1 STD)
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diminish. Recent studies have shown that fracture heal-
ing in elderly patients appears to take place rather slowly
or with insufficient stability due to reduced mineral
density [35–38]. It has also been shown that in vitro dif-
ferentiation of bone marrow stroma cells to osteoblasts
is less successful in cultures from older patients in com-
parison to those from younger patients [39].. Insuffi-
ciency of tissue regeneration in ONFH becomes even
more apparent with regard to fibrosis. In this context,
Sadile et al. evaluated the extension of histological fibro-
sis in a series of specimens from ONFH-biopsies. By
proving a negative correlation, they were able to show
that the extension of reactive fibrosis is a predictor of
outcome of core decompression [40].
Regarding angioneogenesis, an important aspect in the
healing process of ONFH, a decrease in regenerative po-
tential can also be seen. As pluripotent bone marrow
stroma cells decrease in number and potential for differ-
entiation, the organism’s capacity to revascularize necrotic
zones is highly limited. This condition is further aggra-
vated by the aging of existing vessels, known as vascular
aging, which is characterized by a progressive endothelial
cell and smooth muscle cell dysfunction [41, 42].
Overall, it is known that the aging organism presents an
increasing loss of functional tissue cells leading to an on-
going reduction in the ability of the tissues to maintain
and replace themselves [43]. Therefore, it is not surprising
that the success of ONHF therapy decreases with
increasing age, and this is reflected in the rate of postoper-
ative hip survival. The age of forty seems to mark a limit,
with patients aged under forty having a significantly better
chance of long-term hip survival after ACD, whereas
about half of the patients older than 40 have to face ther-
apy failure in the postoperative course. However, in this
context, it must be noted that the short-term postopera-
tive course seems to be similar in all patients, irrespective
of age. As shown in Fig. 3, the Kaplan-Meier curves ap-
pear to be identical for the age groups < 40 and ≥ 40 years
of age until the sixth month of the follow-up period (Fig.
2). Therefore, age-related factors affecting the overall ther-
apy outcome seem to gain in importance only in the fur-
ther postoperative course.
Concerning the parameter “sex”, it is known that the
occurrence of ONFH is distributed unevenly between
the sexes, affecting predominantly men [5, 6]. However,
apart from its uneven distribution which might be due
to still unknown sex-based factors according to Shimizu
et al., sex as a parameter influencing the long-term out-
come of ONFH-therapy had not previously been evalu-
ated [23]. The present study indicates that patients’ sex
seems to have no influence on therapy as the results of
the calculated Kaplan-Meier estimator could not prove
any significant sex-dependent differences in hip survival
(p = 0.48). Therefore, it can be assumed that, based on
current knowledge, the parameter “sex” is not relevant
for the prediction of long-term ONFH therapy outcome.
Table 5 Distribution of possible confounders among age-related subgroups in total numbers and rounded percentages
Possible confounder Age-related ubgroups (count and percentage)
< 30 years ≥ 30/< 40 years ≥ 40/< 50 years ≥ 50 years
Lesion Size < 15% 1 (11.1%) 2 (12.5%) 2 (7.4%) 2 (5.9%)
≥ 15/≤ 30% 4 (44.4%) 8 (50%) 15 (55.6%) 22 (64.7%)
> 30% 4 (44.4%) 6 (37.5%) 10 (37.0%) 10 (29.4%)
Total 9 (100%) 16 (100%) 27 (100%) 34 (100%)
p = 0.92
Alpha angle < 50° 2 (22.2%) 3 (18.8%) 7 (25.9%) 8 (23.5%)
≥ 50°/< 60° 3 (33.3%) 5 (31.3%) 7 (25.9%) 10 (29.4%)
≥ 60° 4 (44.4%) 8 (50.0%) 13 (48.1%) 16 (47.1%)
Total 9 (100%) 16 (100%) 27 (100%) 34 (100%)
p = 0.99
Risk factor No 4 (44.4%) 8 (50.0%) 11 (40.7%) 19 (55.9%)
Yes 5 (55.6%) 8 (50.0%) 16 (59.3%) 15 (44.1%)
Total 9 (100%) 18 (100%) 27 (100%) 34 (100%)
p = 0.69
Treatment type ACD 5 (55.6%) 7 (43.75%) 15 (55.6%) 19 (55.9%)
mACD 4 (44.4%) 9 (56.25%) 12 (44.4%) 15 (44.1%)
Total 9 (100%) 16 (100%) 27 (100%) 34 (100%)
p = 0.86
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However, as calculations revealed some differences in
mean hip survival (male 51.3 months vs. female 61.4
months), the uneven distribution of the number of male
and female study participants has to be taken into ac-
count. With only 20 female study patients, out of a total
study collective of 86, statistical calculations might be
biased and further examination with a greater number of
female participants is required to confirm the study re-
sults. In this context, this study’s finding which indicates
an earlier occurrence of treatment failure in the female
subpopulation has to be verified as well.
As far as functional parameters and changes in pain
levels are concerned, the study results appeared very uni-
form. A distinct amelioration of function of the affected
hip, proved through a significant increase in mHHS from
pre- to postoperative, was seen. A significant decrease in
NRS demonstrated a clear improvement of postoperative
pain levels. These findings were seen in the patients whose
therapy was still successful after the follow-up period and
were nearly identical, irrespective of the patient’s sex or
age. Furthermore, this study’s results show consistent sub-
group changes in mHHS and NRS at the different follow-
up times. It follows that, in case of non-appearance of
treatment failure, the process of rehabilitation is not af-
fected by the parameters sex and age.
The results of the given study are limited by the fact that
patient numbers of the investigated age groups were not
evenly distributed. Therefore, an effect on the statistical
analysis cannot be excluded. By proving a homogenous
distribution of the possible confounders “lesion size”,
“alpha angle”, “risk factors” and “surgery type” within the
subgroups, an unwanted effect on the overall results was
attempted to eliminate (Table 3). However, as there are
further possible confounders which could not be taken
into account in the analysis (e.g. body mass index), a bias
cannot be completely excluded [44]. Furthermore, it must
be taken into account that the results presented in this
study, although focused on the parameters “age” and
“sex”, are based on the therapeutic intervention of core
decompression. Although core decompression and its
modifications are still widely used, its overall status in the
treatment of ONFH has been repeatedly criticized. In their
meta-analysis from 2016, Sadile et.al. were able to prove
that especially classic core decompression does not im-
prove clinical outcomes compared with other joint-
preserving therapies. There even is some indication for
less beneficial overall results [45]. On the whole, deter-
mining the role of core decompression remains difficult
since lots of modifications have been described so far, and
there is a lack of comparing studies. Hence, comparative
analyses of the different surgical and non-surgical tech-
niques regarding age- and sex-related outcome need to be
undertaken in the future to further substantiate this
study’s findings.
Conclusion
The current study shows a distinct age-dependent rate
of hip survival of ONFH patients treated by advanced
core decompression. Therapy failure is significantly
more likely to be seen in patients over 40 years of age.
Patients’ sex does not seem to affect treatment outcome.
For the patients who did not experience therapy failure
during follow-up, postoperative clinical scores were in-
dependent of the parameters age and sex, and the re-
habilitation process was not affected. Since the patient’s
sex and age are unalterable parameters, the study cannot
recommend any specific measures for the treatment of
ONFH. However, it does show that therapy results are
strongly age-dependent and thus it enables valuable pre-
dictions regarding the chances of long-term hip survival.
Abbreviations
ONFH: Osteonecrosis of the femoral head; mHHS: Modified Harris Hip Score;
NRS: Numeric rating scale; ACD: Advanced core decompression;
mACD: Modified advanced core decompression
Acknowledgements
We acknowledge the support by the Deutsche Forschungsgemeinschaft
(DFG, German Research Foundation) and Saarland University within the
funding programme Open Access Publishing.
Ethical approval and consent to participate
The study was approved by the local ethics committee under the number
10-4293. Informed consent was obtained from all patients enrolled in this
study.
Authors’ contributions
SS collected data and wrote the manuscript. MH, TT and FD performed
statistical analysis and contributed in manuscript preparation. SL contributed
in designing the study and revising the manuscript. The authors read and
approved the final manuscript.
Funding
There is no funding source.
Availability of data and materials
The data that supports the findings of this study are available from the
corresponding author upon reasonable request.
Consent for publication
All authors have approved the manuscript for publication.
Competing interests
There are no conflicts (financial and non-financial) to be declared.
Author details
1Department of Orthopaedics & Orthopaedic Surgery, Saarland University,
Kirrberger Strasse 100, 66421 Homburg, Germany. 2Department of
Orthopaedics & Traumatology, University of Duisburg-Essen, Essen, Germany.
Received: 21 January 2020 Accepted: 20 March 2020
References
1. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral
head. J Bone Joint Surg Am. 1995;77:459–74.
2. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med.
1992;326:1473–9. https://doi.org/10.1056/NEJM199205283262206.
3. Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR. Nontraumatic
osteonecrosis of the femoral head: where do we stand today? A ten-year
update. J Bone Joint Surg Am. 2015;97:1604–27. https://doi.org/10.2106/
JBJS.O.00071.
Serong et al. Journal of Orthopaedic Surgery and Research          (2020) 15:124 Page 7 of 8
4. Seamon J, Keller T, Saleh J, Cui Q. The pathogenesis of nontraumatic
osteonecrosis. Arthritis. 2012;2012:601763. https://doi.org/10.1155/2012/
601763.
5. Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH. Prevalence of osteonecrosis
of the femoral head: A nationwide epidemiologic analysis in Korea. J Arthroplasty.
2009;24:1178–83. https://doi.org/10.1016/j.arth.2009.05.022.
6. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide
epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin
Orthop Relat Res. 2010;468:2715–24. https://doi.org/10.1007/s11999-010-1292-x.
7. Camporesi E, Vezzani G, Zanon V, Manelli D, Enten G, Quartesan S, Bosco G.
Review on hyperbaric oxygen treatment in femoral head necrosis. Undersea
Hyperb Med. 2017;44:497–508.
8. Nakamura J, Harada Y, Oinuma K, Iida S, Kishida S, Takahashi K. Spontaneous
repair of asymptomatic osteonecrosis associated with corticosteroid therapy
in systemic lupus erythematosus: 10-year minimum follow-up with MRI.
Lupus. 2010;19:1307–14. https://doi.org/10.1177/0961203310372951.
9. Lee Y-K, Ha Y-C, Cho YJ, Suh KT, Kim S-Y, Won Y-Y, et al. Does zoledronate
prevent femoral head collapse from osteonecrosis? A prospective,
randomized, open-label, multicenter study. J Bone Joint Surg Am. 2015;97:
1142–8. https://doi.org/10.2106/JBJS.N.01157.
10. Disch AC, Matziolis G, Perka C. The management of necrosis-associated and
idiopathic bone-marrow oedema of the proximal femur by intravenous
iloprost. J Bone Joint Surg Br. 2005;87:560–4. https://doi.org/10.1302/0301-
620X.87B4.15658.
11. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of
stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005:164–70.
https://doi.org/10.1097/01.blo.0000157539.67567.03.
12. Lai K-A, Shen W-J, Yang C-Y, Shao C-J, Hsu J-T, Lin R-M. The use of
alendronate to prevent early collapse of the femoral head in patients with
nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg
Am. 2005;87:2155–9. https://doi.org/10.2106/JBJS.D.02959.
13. Vulpiani MC, Vetrano M, Trischitta D, Scarcello L, Chizzi F, Argento G, et al.
Extracorporeal shock wave therapy in early osteonecrosis of the femoral
head: prospective clinical study with long-term follow-up. Arch Orthop
Trauma Surg. 2012;132:499–508. https://doi.org/10.1007/s00402-011-1444-9.
14. Xie K, Mao Y, Qu X, Dai K, Jia Q, Zhu Z, Yan M. High-energy extracorporeal
shock wave therapy for nontraumatic osteonecrosis of the femoral head. J
Orthop Surg Res. 2018;13:25. https://doi.org/10.1186/s13018-017-0705-x.
15. Wang C-J, Huang C-C, Wang J-W, Wong T, Yang Y-J. Long-term results of
extracorporeal shockwave therapy and core decompression in
osteonecrosis of the femoral head with eight- to nine-year follow-up.
Biomed J. 2012;35:481–5. https://doi.org/10.4103/2319-4170.104413.
16. Lieberman JR, Conduah A, Urist MR. Treatment of osteonecrosis of the
femoral head with core decompression and human bone morphogenetic
protein. Clin Orthop Relat Res. 2004:139–45.
17. Landgraeber S, Theysohn JM, Classen T, Jäger M, Warwas S, Hohn H-P,
Kowalczyk W. Advanced core decompression, a new treatment option of
avascular necrosis of the femoral head--a first follow-up. J Tissue Eng Regen
Med. 2013;7:893–900. https://doi.org/10.1002/term.1481.
18. Liu D, Chen Q, Chen Y, Liu Y. Long-term follow-up of early-middle stage
avascular necrosis of femoral head with core decompression and bone
grafting. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012;26:1165–8.
19. Rajagopal M, Balch Samora J, Ellis TJ. Efficacy of core decompression as
treatment for osteonecrosis of the hip: a systematic review. Hip Int. 2012;22:
489–93. https://doi.org/10.5301/HIP.2012.9748.
20. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging
avascular necrosis. J Bone Joint Surg Br. 1995;77:34–41.
21. Classen T, Warwas S, Jäger M, Landgraeber S. Two-year follow-up after
advanced core decompression. J Tissue Eng Regen Med. 2017;11:1308–14.
https://doi.org/10.1002/term.2056.
22. Serong S, Haversath M, Jäger M, Landgraeber S. Prevalence of CAM
deformity and its influence on therapy success in patients with
osteonecrosis of the femoral head. J Tissue Eng Regen Med. 2019. https://
doi.org/10.1002/term.2794.
23. Shimizu J, Okazaki S, Nagoya S, Takahashi N, Kanaya K, Mizuo K, et al.
Susceptibility of males, but not females to developing femoral head
osteonecrosis in response to alcohol consumption. PLoS One. 2016;11:
e0165490. https://doi.org/10.1371/journal.pone.0165490.
24. Gardeniers JWM, Gosling-Gardeniers AC, Rijnen WHC. The ARCO staging
system: generation and evolution since 1991. In: Osteonecrosis: Springer;
2014. p. 215–8.
25. Kumar P, Sen R, Aggarwal S, Agarwal S, Rajnish RK. Reliability of modified
Harris Hip Score as a tool for outcome evaluation of total hip replacements
in Indian population. J Clin Orthop Trauma. 2019;10:128–30. https://doi.org/
10.1016/j.jcot.2017.11.019.
26. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales.
J Clin Nurs. 2005;14:798–804. https://doi.org/10.1111/j.1365-2702.2005.01121.x.
27. Landgraeber S, Warwas S, Claßen T, Jäger M. Modifications to advanced
core decompression for treatment of avascular necrosis of the femoral
head. BMC Musculoskelet Disord. 2017;18:479. https://doi.org/10.1186/
s12891-017-1811-y.
28. Drescher W, Pufe T, Smeets R, Eisenhart-Rothe RV, Jäger M, Tingart M.
Hüftkopfnekrose - Diagnostik und Differenzialtherapie. Z Orthop Unfall.
2011;149:231–40; quiz 241-2. https://doi.org/10.1055/s-0030-1270984.
29. Nötzli HP, Wyss TF, Stoecklin CH, Schmid MR, Treiber K, Hodler J. The
contour of the femoral head-neck junction as a predictor for the risk of
anterior impingement. J Bone Joint Surg Br. 2002;84:556–60.
30. Tingart M, Beckmann J, Opolka A, Matsuura M, Wiech O, Grifka J, Grässel S.
Influence of factors regulating bone formation and remodeling on bone
quality in osteonecrosis of the femoral head. Calcified Tissue International.
2008;82:300–8. https://doi.org/10.1007/s00223-008-9111-z.
31. Karsenty G. How many factors are required to remodel bone? Nat Med.
2000;6:970–1. https://doi.org/10.1038/79655.
32. Li X, Cao X. BMP signaling and skeletogenesis. Ann N Y Acad Sci. 2006;1068:
26–40. https://doi.org/10.1196/annals.1346.006.
33. Durnez A, Paternotte S, Fechtenbaum J, Landewé RBM, Dougados M, Roux
C, Briot K. Increase in bone density in patients with spondyloarthritis during
anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol.
2013;40:1712–8.
34. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al.
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation
and activation. Cell. 1998;93:165–76.
35. Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, et al. Delayed
union and nonunions: epidemiology, clinical issues, and financial aspects.
Injury. 2014;45(Suppl 2):S3–7. https://doi.org/10.1016/j.injury.2014.04.002.
36. Nandra R, Grover L, Porter K. Fracture non-union epidemiology and
treatment. Trauma. 2016;18:3–11.
37. Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM,
Christie J. Refractures in patients at least forty-five years old. a prospective
analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am.
2002;84-A:1528–33.
38. Gruber R, Koch H, Doll BA, Tegtmeier F, Einhorn TA, Hollinger JO. Fracture
healing in the elderly patient. Exp Gerontol. 2006;41:1080–93. https://doi.
org/10.1016/j.exger.2006.09.008.
39. D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related
osteogenic potential of mesenchymal stromal stem cells from human
vertebral bone marrow. J Bone Miner Res. 1999;14:1115–22. https://doi.org/
10.1359/jbmr.1999.14.7.1115.
40. Sadile F, Bernasconi A, Carbone F, Lintz F, Mansueto G. Histological fibrosis
may predict the failure of core decompression in the treatment of
osteonecrosis of the femoral head. Int J Surg. 2017;44:303–8. https://doi.org/
10.1016/j.ijsu.2017.06.079.
41. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al.
Vascular smooth muscle cells undergo telomere-based senescence in
human atherosclerosis: effects of telomerase and oxidative stress. Circ Res.
2006;99:156–64.
42. Mistriotis P, Andreadis ST. Vascular aging: molecular mechanisms and
potential treatments for vascular rejuvenation. Ageing Res Rev. 2017;37:94–
116. https://doi.org/10.1016/j.arr.2017.05.006.
43. Carrington JL. Aging bone and cartilage: cross-cutting issues. Biochem Biophys
Res Commun. 2005;328:700–8. https://doi.org/10.1016/j.bbrc.2004.12.041.
44. Ha Y-C, Kim HJ, Kim S-Y, Kim K-C, Lee Y-K, Koo K-H. Effects of age and body
mass index on the results of transtrochanteric rotational osteotomy for
femoral head osteonecrosis. J Bone Joint Surg Am. 2010;92:314–21. https://
doi.org/10.2106/JBJS.H.01020.
45. Sadile F, Bernasconi A, Russo S, Maffulli N. Core decompression versus other
joint preserving treatments for osteonecrosis of the femoral head: a meta-
analysis. Br Med Bull. 2016;118:33–49. https://doi.org/10.1093/bmb/ldw010.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Serong et al. Journal of Orthopaedic Surgery and Research          (2020) 15:124 Page 8 of 8
